Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses
Identifieur interne : 000A64 ( Pmc/Corpus ); précédent : 000A63; suivant : 000A65Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses
Auteurs : Christin Müller ; Falk W. Schulte ; Kerstin Lange-Grünweller ; Wiebke Obermann ; Ramakanth Madhugiri ; Stephan Pleschka ; John Ziebuhr ; Roland K. Hartmann ; Arnold GrünwellerSource :
- Antiviral Research [ 0166-3542 ] ; 2017.
Abstract
Coronaviruses (CoV) and picornaviruses are plus-strand RNA viruses that use 5′ cap-dependent and cap-independent strategies, respectively, for viral mRNA translation initiation. Here, we analyzed the effects of the plant compound silvestrol, a specific inhibitor of the DEAD-box RNA helicase eIF4A, on viral translation using a dual luciferase assay and virus-infected primary cells. Silvestrol was recently shown to have potent antiviral activity in Ebola virus-infected human macrophages. We found that silvestrol is also a potent inhibitor of cap-dependent viral mRNA translation in CoV-infected human embryonic lung fibroblast (MRC-5) cells. EC50 values of 1.3 nM and 3 nM silvestrol were determined for MERS-CoV and HCoV-229E, respectively. For the highly pathogenic MERS-CoV, the potent antiviral activities of silvestrol were also confirmed using peripheral blood mononuclear cells (PBMCs) as a second type of human primary cells. Silvestrol strongly inhibits the expression of CoV structural and nonstructural proteins (N, nsp8) and the formation of viral replication/transcription complexes. Furthermore, potential antiviral effects against human rhinovirus (HRV) A1 and poliovirus type 1 (PV), representing different species in the genus
Url:
DOI: 10.1016/j.antiviral.2017.12.010
PubMed: 29258862
PubMed Central: 7113723
Links to Exploration step
PMC:7113723Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</title><author><name sortKey="Muller, Christin" sort="Muller, Christin" uniqKey="Muller C" first="Christin" last="Müller">Christin Müller</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</nlm:aff></affiliation></author><author><name sortKey="Schulte, Falk W" sort="Schulte, Falk W" uniqKey="Schulte F" first="Falk W." last="Schulte">Falk W. Schulte</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Lange Grunweller, Kerstin" sort="Lange Grunweller, Kerstin" uniqKey="Lange Grunweller K" first="Kerstin" last="Lange-Grünweller">Kerstin Lange-Grünweller</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Obermann, Wiebke" sort="Obermann, Wiebke" uniqKey="Obermann W" first="Wiebke" last="Obermann">Wiebke Obermann</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Madhugiri, Ramakanth" sort="Madhugiri, Ramakanth" uniqKey="Madhugiri R" first="Ramakanth" last="Madhugiri">Ramakanth Madhugiri</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation></author><author><name sortKey="Pleschka, Stephan" sort="Pleschka, Stephan" uniqKey="Pleschka S" first="Stephan" last="Pleschka">Stephan Pleschka</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</nlm:aff></affiliation></author><author><name sortKey="Ziebuhr, John" sort="Ziebuhr, John" uniqKey="Ziebuhr J" first="John" last="Ziebuhr">John Ziebuhr</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</nlm:aff></affiliation></author><author><name sortKey="Hartmann, Roland K" sort="Hartmann, Roland K" uniqKey="Hartmann R" first="Roland K." last="Hartmann">Roland K. Hartmann</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Grunweller, Arnold" sort="Grunweller, Arnold" uniqKey="Grunweller A" first="Arnold" last="Grünweller">Arnold Grünweller</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">29258862</idno><idno type="pmc">7113723</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113723</idno><idno type="RBID">PMC:7113723</idno><idno type="doi">10.1016/j.antiviral.2017.12.010</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000A64</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</title><author><name sortKey="Muller, Christin" sort="Muller, Christin" uniqKey="Muller C" first="Christin" last="Müller">Christin Müller</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</nlm:aff></affiliation></author><author><name sortKey="Schulte, Falk W" sort="Schulte, Falk W" uniqKey="Schulte F" first="Falk W." last="Schulte">Falk W. Schulte</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Lange Grunweller, Kerstin" sort="Lange Grunweller, Kerstin" uniqKey="Lange Grunweller K" first="Kerstin" last="Lange-Grünweller">Kerstin Lange-Grünweller</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Obermann, Wiebke" sort="Obermann, Wiebke" uniqKey="Obermann W" first="Wiebke" last="Obermann">Wiebke Obermann</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Madhugiri, Ramakanth" sort="Madhugiri, Ramakanth" uniqKey="Madhugiri R" first="Ramakanth" last="Madhugiri">Ramakanth Madhugiri</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation></author><author><name sortKey="Pleschka, Stephan" sort="Pleschka, Stephan" uniqKey="Pleschka S" first="Stephan" last="Pleschka">Stephan Pleschka</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</nlm:aff></affiliation></author><author><name sortKey="Ziebuhr, John" sort="Ziebuhr, John" uniqKey="Ziebuhr J" first="John" last="Ziebuhr">John Ziebuhr</name><affiliation><nlm:aff id="aff1">Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</nlm:aff></affiliation></author><author><name sortKey="Hartmann, Roland K" sort="Hartmann, Roland K" uniqKey="Hartmann R" first="Roland K." last="Hartmann">Roland K. Hartmann</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author><author><name sortKey="Grunweller, Arnold" sort="Grunweller, Arnold" uniqKey="Grunweller A" first="Arnold" last="Grünweller">Arnold Grünweller</name><affiliation><nlm:aff id="aff2">Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</nlm:aff></affiliation></author></analytic><series><title level="j">Antiviral Research</title><idno type="ISSN">0166-3542</idno><idno type="eISSN">1872-9096</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Coronaviruses (CoV) and picornaviruses are plus-strand RNA viruses that use 5′ cap-dependent and cap-independent strategies, respectively, for viral mRNA translation initiation. Here, we analyzed the effects of the plant compound silvestrol, a specific inhibitor of the DEAD-box RNA helicase eIF4A, on viral translation using a dual luciferase assay and virus-infected primary cells. Silvestrol was recently shown to have potent antiviral activity in Ebola virus-infected human macrophages. We found that silvestrol is also a potent inhibitor of cap-dependent viral mRNA translation in CoV-infected human embryonic lung fibroblast (MRC-5) cells. EC<sub>50</sub> values of 1.3 nM and 3 nM silvestrol were determined for MERS-CoV and HCoV-229E, respectively. For the highly pathogenic MERS-CoV, the potent antiviral activities of silvestrol were also confirmed using peripheral blood mononuclear cells (PBMCs) as a second type of human primary cells. Silvestrol strongly inhibits the expression of CoV structural and nonstructural proteins (N, nsp8) and the formation of viral replication/transcription complexes. Furthermore, potential antiviral effects against human rhinovirus (HRV) A1 and poliovirus type 1 (PV), representing different species in the genus <italic>Enterovirus</italic> (family <italic>Picornaviridae</italic>), were investigated. The two viruses employ an internal ribosomal entry site (IRES)-mediated translation initiation mechanism. For PV, which is known to require the activity of eIF4A, an EC<sub>50</sub> value of 20 nM silvestrol was determined in MRC-5 cells. The higher EC<sub>50</sub> value of 100 nM measured for HRV A1 indicates a less critical role of eIF4A activity in HRV A1 IRES-mediated translation initiation. Taken together, the data reveal a broad-spectrum antiviral activity of silvestrol in infected primary cells by inhibiting eIF4A-dependent viral mRNA translation.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Biedenkopf, N" uniqKey="Biedenkopf N">N. Biedenkopf</name></author><author><name sortKey="Lange Grunweller, K" uniqKey="Lange Grunweller K">K. Lange-Grünweller</name></author><author><name sortKey="Schulte, F W" uniqKey="Schulte F">F.W. Schulte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bordeleau, M E" uniqKey="Bordeleau M">M.E. Bordeleau</name></author><author><name sortKey="Mori, A" uniqKey="Mori A">A. Mori</name></author><author><name sortKey="Oberer, M" uniqKey="Oberer M">M. Oberer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cencic, R" uniqKey="Cencic R">R. Cencic</name></author><author><name sortKey="Carrier, M" uniqKey="Carrier M">M. Carrier</name></author><author><name sortKey="Galicia Vazquez, G" uniqKey="Galicia Vazquez G">G. Galicia-Vázquez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chu, J" uniqKey="Chu J">J. Chu</name></author><author><name sortKey="Galicia Vazquez, G" uniqKey="Galicia Vazquez G">G. Galicia-Vázquez</name></author><author><name sortKey="Cencic, R" uniqKey="Cencic R">R. Cencic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hinnebusch, A G" uniqKey="Hinnebusch A">A.G. Hinnebusch</name></author><author><name sortKey="Ivanov, I P" uniqKey="Ivanov I">I.P. Ivanov</name></author><author><name sortKey="Sonenberg, N" uniqKey="Sonenberg N">N. Sonenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kogure, T" uniqKey="Kogure T">T. Kogure</name></author><author><name sortKey="Kinghorn, A D" uniqKey="Kinghorn A">A.D. Kinghorn</name></author><author><name sortKey="Yan, I" uniqKey="Yan I">I. Yan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, K M" uniqKey="Lee K">K.M. Lee</name></author><author><name sortKey="Chen, C J" uniqKey="Chen C">C.J. Chen</name></author><author><name sortKey="Shih, S R" uniqKey="Shih S">S.R. Shih</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lucas, D M" uniqKey="Lucas D">D.M. Lucas</name></author><author><name sortKey="Edwards, R B" uniqKey="Edwards R">R.B. Edwards</name></author><author><name sortKey="Lozanski, G" uniqKey="Lozanski G">G. Lozanski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lundin, A" uniqKey="Lundin A">A. Lundin</name></author><author><name sortKey="Dijkman, R" uniqKey="Dijkman R">R. Dijkman</name></author><author><name sortKey="Bergstrom, T" uniqKey="Bergstrom T">T. Bergström</name></author><author><name sortKey="Kann, N" uniqKey="Kann N">N. Kann</name></author><author><name sortKey="Adamiak, B" uniqKey="Adamiak B">B. Adamiak</name></author><author><name sortKey="Hannoun, C" uniqKey="Hannoun C">C. Hannoun</name></author><author><name sortKey="Kindler, E" uniqKey="Kindler E">E. Kindler</name></author><author><name sortKey="J Nsd Ttir, H R" uniqKey="J Nsd Ttir H">H.R. Jónsdóttir</name></author><author><name sortKey="Muth, D" uniqKey="Muth D">D. Muth</name></author><author><name sortKey="Kint, J" uniqKey="Kint J">J. Kint</name></author><author><name sortKey="Forlenza, M" uniqKey="Forlenza M">M. Forlenza</name></author><author><name sortKey="Muller, M A" uniqKey="Muller M">M.A. Müller</name></author><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name></author><author><name sortKey="Thiel, V" uniqKey="Thiel V">V. Thiel</name></author><author><name sortKey="Trybala, E" uniqKey="Trybala E">E. Trybala</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Madhugiri, R" uniqKey="Madhugiri R">R. Madhugiri</name></author><author><name sortKey="Fricke, M" uniqKey="Fricke M">M. Fricke</name></author><author><name sortKey="Marz, M" uniqKey="Marz M">M. Marz</name></author><author><name sortKey="Ziebuhr, J" uniqKey="Ziebuhr J">J. Ziebuhr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, C" uniqKey="Muller C">C. Müller</name></author><author><name sortKey="Karl, N" uniqKey="Karl N">N. Karl</name></author><author><name sortKey="Ziebuhr, J" uniqKey="Ziebuhr J">J. Ziebuhr</name></author><author><name sortKey="Pleschka, S" uniqKey="Pleschka S">S. Pleschka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, L" uniqKey="Pan L">L. Pan</name></author><author><name sortKey="Woodard, J L" uniqKey="Woodard J">J.L. Woodard</name></author><author><name sortKey="Lucas, D M" uniqKey="Lucas D">D.M. Lucas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Patton, J T" uniqKey="Patton J">J.T. Patton</name></author><author><name sortKey="Lustberg, M E" uniqKey="Lustberg M">M.E. Lustberg</name></author><author><name sortKey="Lozanski, G" uniqKey="Lozanski G">G. Lozanski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pelletier, J" uniqKey="Pelletier J">J. Pelletier</name></author><author><name sortKey="Graff, J" uniqKey="Graff J">J. Graff</name></author><author><name sortKey="Ruggero, D" uniqKey="Ruggero D">D. Ruggero</name></author><author><name sortKey="Sonenberg, N" uniqKey="Sonenberg N">N. Sonenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rubio, C A" uniqKey="Rubio C">C.A. Rubio</name></author><author><name sortKey="Weisburd, B" uniqKey="Weisburd B">B. Weisburd</name></author><author><name sortKey="Holderfield, M" uniqKey="Holderfield M">M. Holderfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sadlish, H" uniqKey="Sadlish H">H. Sadlish</name></author><author><name sortKey="Galicia Vazquez, G" uniqKey="Galicia Vazquez G">G. Galicia-Vazquez</name></author><author><name sortKey="Paris, C G" uniqKey="Paris C">C.G. Paris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saradhi, U V" uniqKey="Saradhi U">U.V. Saradhi</name></author><author><name sortKey="Gupta, S V" uniqKey="Gupta S">S.V. Gupta</name></author><author><name sortKey="Chiu, M" uniqKey="Chiu M">M. Chiu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schatz, J H" uniqKey="Schatz J">J.H. Schatz</name></author><author><name sortKey="Oricchio, E" uniqKey="Oricchio E">E. Oricchio</name></author><author><name sortKey="Wolfe, A L" uniqKey="Wolfe A">A.L. Wolfe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schlereth, J" uniqKey="Schlereth J">J. Schlereth</name></author><author><name sortKey="Grunweller, A" uniqKey="Grunweller A">A. Grünweller</name></author><author><name sortKey="Biedenkopf, N" uniqKey="Biedenkopf N">N. Biedenkopf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Su, B N" uniqKey="Su B">B.N. Su</name></author><author><name sortKey="Chai, H" uniqKey="Chai H">H. Chai</name></author><author><name sortKey="Mi, Q" uniqKey="Mi Q">Q. Mi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thompson, S R" uniqKey="Thompson S">S.R. Thompson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weik, M" uniqKey="Weik M">M. Weik</name></author><author><name sortKey="Modrof, J" uniqKey="Modrof J">J. Modrof</name></author><author><name sortKey="Klenk, H D" uniqKey="Klenk H">H.D. Klenk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, J Y" uniqKey="Zhu J">J.Y. Zhu</name></author><author><name sortKey="Lavrik, I N" uniqKey="Lavrik I">I.N. Lavrik</name></author><author><name sortKey="Mahlknecht, U" uniqKey="Mahlknecht U">U. Mahlknecht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ziebuhr, J" uniqKey="Ziebuhr J">J. Ziebuhr</name></author><author><name sortKey="Siddell, S G" uniqKey="Siddell S">S.G. Siddell</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Antiviral Res</journal-id><journal-id journal-id-type="iso-abbrev">Antiviral Res</journal-id><journal-title-group><journal-title>Antiviral Research</journal-title></journal-title-group><issn pub-type="ppub">0166-3542</issn><issn pub-type="epub">1872-9096</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29258862</article-id><article-id pub-id-type="pmc">7113723</article-id><article-id pub-id-type="publisher-id">S0166-3542(17)30638-1</article-id><article-id pub-id-type="doi">10.1016/j.antiviral.2017.12.010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Müller</surname><given-names>Christin</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Schulte</surname><given-names>Falk W.</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Lange-Grünweller</surname><given-names>Kerstin</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Obermann</surname><given-names>Wiebke</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Madhugiri</surname><given-names>Ramakanth</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Pleschka</surname><given-names>Stephan</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Ziebuhr</surname><given-names>John</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Hartmann</surname><given-names>Roland K.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Grünweller</surname><given-names>Arnold</given-names></name><email>gruenwel@staff.uni-marburg.de</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">∗</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Institut für Medizinische Virologie, Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Gießen, Germany</aff><aff id="aff2"><label>b</label>Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marbacher Weg 6, 35037 Marburg, Germany</aff><aff id="aff3"><label>c</label>Deutsches Zentrum für Infektionsforschung (DZIF) at the partner site Gießen-Marburg-Langen, Germany</aff><author-notes><corresp id="cor1"><label>∗</label>Corresponding author. <email>gruenwel@staff.uni-marburg.de</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">Both authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2017</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2017</year></pub-date><volume>150</volume><fpage>123</fpage><lpage>129</lpage><history><date date-type="received"><day>5</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>12</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Coronaviruses (CoV) and picornaviruses are plus-strand RNA viruses that use 5′ cap-dependent and cap-independent strategies, respectively, for viral mRNA translation initiation. Here, we analyzed the effects of the plant compound silvestrol, a specific inhibitor of the DEAD-box RNA helicase eIF4A, on viral translation using a dual luciferase assay and virus-infected primary cells. Silvestrol was recently shown to have potent antiviral activity in Ebola virus-infected human macrophages. We found that silvestrol is also a potent inhibitor of cap-dependent viral mRNA translation in CoV-infected human embryonic lung fibroblast (MRC-5) cells. EC<sub>50</sub> values of 1.3 nM and 3 nM silvestrol were determined for MERS-CoV and HCoV-229E, respectively. For the highly pathogenic MERS-CoV, the potent antiviral activities of silvestrol were also confirmed using peripheral blood mononuclear cells (PBMCs) as a second type of human primary cells. Silvestrol strongly inhibits the expression of CoV structural and nonstructural proteins (N, nsp8) and the formation of viral replication/transcription complexes. Furthermore, potential antiviral effects against human rhinovirus (HRV) A1 and poliovirus type 1 (PV), representing different species in the genus <italic>Enterovirus</italic> (family <italic>Picornaviridae</italic>), were investigated. The two viruses employ an internal ribosomal entry site (IRES)-mediated translation initiation mechanism. For PV, which is known to require the activity of eIF4A, an EC<sub>50</sub> value of 20 nM silvestrol was determined in MRC-5 cells. The higher EC<sub>50</sub> value of 100 nM measured for HRV A1 indicates a less critical role of eIF4A activity in HRV A1 IRES-mediated translation initiation. Taken together, the data reveal a broad-spectrum antiviral activity of silvestrol in infected primary cells by inhibiting eIF4A-dependent viral mRNA translation.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="fx1_lrg"></graphic></fig></p></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>•</label><p id="p0010">The eIF4A inhibitor silvestrol is a potent antiviral compound that inhibits the replication of coronaviruses.</p></list-item><list-item id="u0015"><label>•</label><p id="p0015">Silvestrol is also effective against picornaviruses with an eIF4A-dependent Type 1 IRES element.</p></list-item><list-item id="u0020"><label>•</label><p id="p0020">In primary cells silvestrol has potent antiviral activity and low toxicity.</p></list-item><list-item id="u0025"><label>•</label><p id="p0025">Targeting the host factor eIF4A is a promising broad-spectrum antiviral strategy.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Silvestrol</kwd><kwd>Coronavirus</kwd><kwd>Picornavirus</kwd><kwd>eIF4A</kwd><kwd>Cap-dependent translation</kwd><kwd>IRES</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">We have recently identified the natural compound silvestrol as a potent antiviral molecule to inhibit Ebola virus (EBOV) replication (<xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>). Silvestrol can be isolated from plants of the genus <italic>Aglaia</italic>. It belongs to the flavaglines, which have a cyclopenta[<italic>b</italic>]benzofuran skeleton in common (<xref rid="bib12" ref-type="bibr">Pan et al., 2014</xref>). Recently, a CRISPR/Cas-based genetic proof of silvestrol's target specificity for the DEAD-box RNA helicase eIF4A was provided (<xref rid="bib4" ref-type="bibr">Chu et al., 2016</xref>). This enzyme is required to unwind stable RNA secondary structures in 5′ UTRs of capped mRNAs to create a binding platform for the 43S preinitiation complex which then scans the 5′ UTR for the start codon to initiate protein synthesis (<xref rid="bib5" ref-type="bibr">Hinnebusch et al., 2016</xref>). Binding of silvestrol to eIF4A increases its affinity to the mRNA, thereby stalling the helicase to its substrate (<xref rid="bib16" ref-type="bibr">Sadlish et al., 2013</xref>). This might lead to depletion of eIF4A from the translation initiation complex eIF4F that recognizes the m7GpppN cap structure of mRNAs (<xref rid="bib14" ref-type="bibr">Pelletier et al., 2015</xref>). Silvestrol is cytotoxic at low nanomolar concentrations to a large number of cancer cell lines and was also shown to exert strong antitumorigenic effects in several tumor mouse models (<xref rid="bib3" ref-type="bibr">Cencic et al., 2009</xref>, <xref rid="bib6" ref-type="bibr">Kogure et al., 2013</xref>, <xref rid="bib13" ref-type="bibr">Patton et al., 2015</xref>). Importantly, in non-cancer cells and primary cells, silvestrol seems to be well tolerated up to low micromolar concentrations (<xref rid="bib20" ref-type="bibr">Su et al., 2006</xref>, <xref rid="bib24" ref-type="bibr">Zhu et al., 2007</xref>, <xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>). The reasons are so far not well understood, however several proto-oncogenes that are sensitive to silvestrol harbor extended 5′UTRs with extensive RNA secondary structure elements. Therefore, it has been proposed that targeting eIF4A by silvestrol might lead to mRNA discrimination during translation (<xref rid="bib3" ref-type="bibr">Cencic et al., 2009</xref>, <xref rid="bib15" ref-type="bibr">Rubio et al., 2014</xref>). Long and structured 5′ UTRs are also often found in capped viral mRNAs like those from EBOV (<xref rid="bib23" ref-type="bibr">Weik et al., 2002</xref>, <xref rid="bib19" ref-type="bibr">Schlereth et al., 2016</xref>). In line with this, we have found that low nanomolar concentrations of silvestrol strongly reduce EBOV titers in primary human macrophages by efficiently decreasing viral protein expression without having cytotoxic side effects at concentrations of effective antiviral activity (<xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>). Also many plus-strand (+) RNA viruses, such as corona- and picornaviruses, carry long and highly structured 5′ UTRs with important functions in viral replication and/or translation initiation (reviewed in <xref rid="bib10" ref-type="bibr">Madhugiri et al., 2016</xref>). We therefore asked the question whether these viruses are also sensitive to silvestrol treatment and if this sensitivity differs among viruses using alternative mechanisms of translation initiation.</p><p id="p0035">Here we established a cellular dual luciferase reporter assay which allows us to rapidly screen for inhibition of eIF4A-dependent translation initiation on viral 5′ UTRs by silvestrol and related compounds. Subsequently, we analyzed potential antiviral effects of silvestrol in human primary cells (human embryonic lung fibroblasts (MRC-5) or peripheral blood mononuclear cells (PBMCs)) that were infected with the Middle East Respiratory Syndrome coronavirus (MERS-CoV) or human coronavirus 229E (HCoV-229E). Both (+) ssRNA viruses use a 5′ cap-dependent mechanism of translation initiation and carry highly structured 5′ UTRs. We also analyzed the effects of silvestrol on replication of two (+) ssRNA viruses of the <italic>Picornaviridae</italic> family, human rhinovirus A1 (HRV A1) and poliovirus type 1 (PV), because it is known that picornaviruses, although utilizing an IRES-dependent mechanism for viral mRNA translation, still require the action of host factors such as eIF4A (<xref rid="bib2" ref-type="bibr">Bordeleau et al., 2006</xref>).</p></sec><sec id="sec2"><label>2</label><title>Material and methods</title><sec id="sec2.1"><label>2.1</label><title>Cells and viruses</title><p id="p0040">Huh-7 cells, African green monkey kidney cells (Vero cells), HeLa cells and primary human lung fibroblasts (MRC-5 cells) were grown in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) at 37 °C and 5% CO<sub>2</sub>. HepG2 cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FCS at 37 °C and 5% CO<sub>2</sub>. HCoV-229E, MERS-CoV (EMC/2012), HRV A1 and PV (strain Mahoney) were obtained from the virus collection of the Institute of Medical Virology, Justus Liebig University Gießen.</p></sec><sec id="sec2.2"><label>2.2</label><title>Reagent</title><p id="p0045">Silvestrol was obtained from Medchemexpress (LLC, Princeton, USA; purity >98%). A stock solution of 6 mM was prepared in DMSO (sterile-filtered; Carl Roth, Germany) and diluted working solutions were prepared in DMEM or IMDM. Control cells were treated with corresponding DMSO dilutions lacking silvestrol.</p></sec><sec id="sec2.3"><label>2.3</label><title>Cloning of the dual luciferase constructs</title><p id="p0050">All 5′ UTRs were cloned into the plasmid pFR_HCV_xb containing an HSV-TK promoter, the firefly luciferase gene, an HCV IRES and the renilla luciferase gene. The different 5′ UTRs (NP: 414 bp, 38% GC; VP35: 97 bp, 35% GC; VP40: 89 bp, 33% GC; GP: 139 bp, 41% GC; VP30: 212 bp, 33% GC; VP24: 460 bp, 40% GC; L: 80 bp, 34% GC; ß-Globin: 50 bp, 44% GC; ß-Actin: 84 bp, 76% GC; PIM1: 157 bp, 75% GC; HCoV-229E: 292 bp, 41% GC; MERS-CoV: 278 bp, 44% GC) were cloned downstream to the HSV-TK promoter and directly followed by the firefly luciferase AUG start codon. All primers were designed by the software <italic>SnapGene</italic><sup><italic>®</italic></sup><italic>3.3.3</italic> (GSL Biotech LLC) and their sequences can be provided upon request.</p></sec><sec id="sec2.4"><label>2.4</label><title>Dual-luciferase reporter assay</title><p id="p0055">The day before transfection, 2 × 10<sup>4</sup> HepG2 cells per well were seeded in a 96-well plate (Greiner Bio One International GmbH) in 200 μL IMDM (Lonza) supplemented with 10% FCS (Biochrom AG) and incubated at 37 °C, 5% CO<sub>2</sub>. The transfection was performed using 100 μL Opti-MEM (Thermo Fisher Scientific). For transfection of five wells, 0.5 μg of the reporter construct DNA were diluted in 25 μL of Opti-MEM. In parallel, 0.5 μL of Lipofectamine<sup>®</sup> 2000 Transfection Reagent (Thermo Fisher Scientific) were mixed with 24.5 μL of Opti-MEM. Both samples were preincubated for 5 min at room temperature, then combined and incubated for another 15 min at room temperature. Then, 10 μL of the solution were added to each well containing the cells in 100 μL Opti-MEM medium. The plates were incubated at 37 °C and 5% CO<sub>2</sub>. 4–6 h post transfection, the medium was aspirated and substituted with 200 μL fresh medium (IMDM + 10% FCS) containing the appropriate silvestrol concentration. As control, the added amount of microliters of silvestrol solution was replaced with the same volume of a solution containing the same DMSO concentration but lacking silvestrol. Following incubation of the cells for 48 h at 37 °C at 5% CO<sub>2,</sub> a Dual-Luciferase<sup>®</sup> Reporter Assay (Promega) was performed according to the manufacturer's instructions. Measurements were done using a Tecan Safire 2 Multimode Reader.</p></sec><sec id="sec2.5"><label>2.5</label><title>Cell toxicity</title><p id="p0060">The cytotoxic concentration 50% (CC<sub>50</sub>) of silvestrol was determined by incubating cells, which were seeded near confluency in FCS-free medium, with serial dilutions of silvestrol in a 96-well format. After incubation for 24 h, 200 μL of MTT-mix (DMEM supplemented with 10% FCS containing 250 μg/ml tetrazolium bromide, Sigma) was added to each well. Cells were further incubated for 90–120 min at 37 °C and subsequently fixed with 3.7% paraformaldehyde in PBS. Tetrazolium crystals were dissolved by adding 200 μL isopropanol to each well and absorbance at 490 nm was determined using an ELISA reader (BioTek). To determine the CC<sub>50</sub>, the MTT values were calculated in percentage with the respective DMSO control set as 100% (see section <xref rid="sec2.4" ref-type="sec">2.4</xref>). CC<sub>50</sub> values were calculated by non-linear regression analysis using GraphPad Prism 5.0 (GraphPad Software).</p></sec><sec id="sec2.6"><label>2.6</label><title>Antiviral activity</title><p id="p0065">To determine the effective concentration 50% (EC<sub>50</sub>) of silvestrol, cell cultures were infected with the respective virus at an MOI of 0.1 for 1 h in PBS/BA/P/S (PBS containing 0.2% BSA, 1 mM MgCl<sub>2</sub>, 0.9 mM CaCl<sub>2</sub>, 100 U/ml penicillin and 100 mg/ml streptomycin) at 33 °C (for HCoV-229E and HRV A1) or 37 °C (for MERS-CoV and PV). After removing the inoculum, cells were incubated with FCS-free DMEM containing different inhibitor concentrations. Supernatants were collected at 24 h post infection (p.i.) and virus titers were analyzed by plaque assay. Briefly, cells were seeded in 24-well plates and inoculated for 1 h with 10-fold virus dilutions in PBS/BA/P/S. Next, the virus inoculum was replaced with Avicel-containing medium (1xMEM [Gibco], 1.25% Avicel [FMC Biopolymer]). At 24 h p.i., the plates were washed with PBS, fixed with 3.7% PFA in PBS and the cell layer was stained with 0.15% crystal violet. To calculate EC<sub>50</sub> values, the virus titer determined for virus-infected cells treated with DMSO only (see section <xref rid="sec2.4" ref-type="sec">2.4</xref>) was set to 100% and titers obtained for silvestrol-treated cells were calculated in relation to it. EC<sub>50</sub> values were calculated by non-linear regression analysis using GraphPad Prism 5.0 (GraphPad Software).</p></sec><sec id="sec2.7"><label>2.7</label><title>Western blot analysis</title><p id="p0070">Viral protein accumulation was analyzed by Western blot analysis. MRC-5 or Huh-7 cells were infected with HCoV-229E at an MOI of 3. At 1 h p.i., the indicated concentrations of silvestrol in DMEM supplemented with antibiotics were added to the cells for 12 h and 48 h, respectively. The cells were lysed with NP40-containing buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% NP40, 1x protease inhibitor cocktail [Sigma-Aldrich]). Proteins were separated by 10% SDS-PAGE and blotted onto a nitrocellulose membrane (Amersham). Membranes were incubated with mouse anti-nucleocapsid protein mAb (Ingenasa), rabbit antiserum specific for HCoV-229E nonstructural protein 8 (nsp8) (<xref rid="bib25" ref-type="bibr">Ziebuhr and Siddell, 1999</xref>) and rabbit anti-actin antibody (Abcam), respectively, each diluted 1:1000 in PBS containing 1% bovine serum albumin (BSA). Following incubation for 60 min, the membranes were extensively washed with PBS and incubated with appropriate secondary antibodies (IRDye-conjugated anti-mouse and anti-rabbit mAb [Li-Cor], respectively) diluted 1:10,000 in PBS containing 1% BSA. After 1 h, membranes were washed and analyzed using the LI-COR Odyssey imaging system.</p></sec><sec id="sec2.8"><label>2.8</label><title>Immunofluorescence</title><p id="p0075">Immunofluorescence was performed as described previously (<xref rid="bib11" ref-type="bibr">Müller et al., 2016</xref>). Briefly, MRC-5 cells were infected with HCoV-229E (MOI of 3) and treated with the indicated concentrations of silvestrol for 12 h p.i. or left untreated. Then, the cells were fixed with ice-cold methanol and stained with mouse anti-dsRNA mAb (J2, SCICONS English & Scientific Consulting Kft.) and polyclonal rabbit anti-HCoV-229E nsp8 serum (<xref rid="bib25" ref-type="bibr">Ziebuhr and Siddell, 1999</xref>). As secondary antibodies, Alexa Fluor 594 goat anti-mouse IgG and Alexa Fluor 488 F(ab’)2 fragment of goat anti-rabbit IgG (Thermo Fisher Scientific) were used. Confocal microscopy was done using a Leica SP05 CLSM and LAS-AF software (Leica).</p></sec></sec><sec id="sec3"><label>3</label><title>Results and discussion</title><sec id="sec3.1"><label>3.1</label><title>Effects of silvestrol on translation of a luciferase reporter mRNA fused to viral 5’ UTRs</title><p id="p0080">In our previous study we identified silvestrol as an efficient inhibitor of translation of several EBOV mRNAs and EBOV replication. To understand the effects of silvestrol on cap-dependent viral protein synthesis in more detail, we fused the 5′ UTRs of all seven EBOV mRNAs to the firefly luciferase coding sequence in a dual luciferase reporter plasmid (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A). Expression of the fusion genes was driven by the HSV-TK promoter, and the corresponding mRNA transcripts underwent co-transcriptional 5′-terminal capping by the respective host factors. The bicistronic reporter transcripts harbor a hepatitis C virus (HCV) IRES element downstream of the firefly luciferase ORF. This type III IRES directs Renilla luciferase gene translation by a 5′-cap- and eIF4A-independent mechanism (<xref rid="bib2" ref-type="bibr">Bordeleau et al., 2006</xref>, <xref rid="bib7" ref-type="bibr">Lee et al., 2017</xref>) and was used to normalize transfection efficiencies (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A). The 5′ UTR of the mRNA encoding the oncogenic kinase PIM1, known to be highly sensitive to inhibition of eIF4A by silvestrol (<xref rid="bib18" ref-type="bibr">Schatz et al., 2011</xref>), served as a positive control, while the unstructured and short 5′ UTRs of the ß-globin and ß-actin mRNAs were used as negative controls. Concentrations of 5 or 10 nM silvestrol inhibited firefly luciferase expression of the ß-globin construct not at all, and that of the ß-actin construct by not more than 10%, whereas the same silvestrol concentrations resulted in ∼40% inhibition for the PIM1 construct (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B). As a further control we analyzed the 5′ UTR of the classical swine fever virus (CSFV) which contains an eIF4A-independent type III IRES element. As expected, no sensitivity towards silvestrol could be observed in the dual luciferase assay (Suppl. <xref rid="appsec1" ref-type="sec">Fig. S1</xref>). For all seven EBOV 5′ UTR constructs, the inhibitory effects of 10 nM silvestrol clearly exceeded the effects of the negative controls, with firefly luciferase activities decreasing by 23% (VP40 matrix protein) and up to 33% (L, RNA-directed RNA polymerase L). This is consistent with our previous results obtained for EBOV-infected macrophages (<xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>), where we observed efficient inhibition of viral mRNA translation at 10 nM silvestrol, although the effects of the same silvestrol concentration on reporter gene expression were generally less pronounced than on EBOV replication. In summary, we conclude that the dual luciferase assay is a suitable and reliable system to analyze the eIF4A dependence of 5′-capped viral mRNAs as an initial screen before infecting cells with pathogenic viruses.<fig id="fig1"><label>Fig. 1</label><caption><p>Analysis of silvestrol effects on reporter gene activity mediated by viral 5′ UTRs. (<bold>A</bold>) Schematic presentation of the dual luciferase reporter vector. The HCV IRES-driven expression of the Renilla luciferase is eIF4A-independent and was used to normalize transfection efficiencies. (<bold>B</bold>) Effects of 5 and 10 nM silvestrol on Firefly luciferase activity. The seven 5′ UTRs of EBOV were cloned upstream of the reporter gene. As negative controls the 5′ UTRs of the ß-globin and the ß-actin mRNAs were analyzed. The 5′ UTR of <italic>PIM1</italic> served as a positive control. (<bold>C</bold>) Effects of silvestrol on reporter gene expression in the context of 5′ UTRs from coronaviruses HCoV-229E and MERS-CoV. All measured values were normalized to corresponding DMSO controls. Standard errors of the mean of at least 8 independent experiments are shown.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"></graphic></fig></p><p id="p0085">We next applied the reporter assay to the study of silvestrol effects on the translation of mRNAs harboring 5′ UTRs derived from (+) ssRNA viruses. We cloned the 5′ UTRs of the human coronavirus HCoV-229E (which causes mild common cold-like symptoms) and of the highly pathogenic MERS-CoV into our reporter plasmid. In both cases, a relatively strong decrease of luciferase activity in the same range as for the PIM1 positive control (∼40%) was measured at a silvestrol concentration of 10 nM (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C), indicating that also polycistronic mRNAs of (+) ssRNA viruses depend on eIF4A and may thus be suitable targets for silvestrol treatment.</p><p id="p0090">Coronaviruses utilize cap-dependent translation initiation mechanisms and contain structured 5′ UTRs in their genome- and subgenome-length mRNAs. Other viruses, such as the picornaviruses HRV A1 or PV translate their mRNAs in a 5’ cap-independent mechanism via IRES elements within their 5′ UTRs (<xref rid="bib21" ref-type="bibr">Thompson, 2012</xref>). Nevertheless, picornaviruses require the action of translation initiation factors, including eIF4A, for initiating IRES-dependent translation (<xref rid="bib2" ref-type="bibr">Bordeleau et al., 2006</xref>). Therefore we decided to include HRV A1 and PV in the following experiments.</p></sec><sec id="sec3.2"><label>3.2</label><title>Effects of silvestrol on viruses with 5′-capped or IRES-containing mRNAs</title><p id="p0095">Next, we analyzed the effects of silvestrol on viral titers in Vero cells (derived from the kidney of a normal healthy African green monkey with loss of the type I IFN cluster) and the cancer cell lines Huh-7 and HeLa. EC<sub>50</sub> and EC<sub>90</sub> values (see <xref rid="tbl1" ref-type="table">Table 1</xref>) were determined using cell lines infected with HCoV-229E, HRV A1 and PV, respectively, at an MOI of 0.1. Following inoculation of the infected cells with the appropriate virus, silvestrol was added in increasing concentrations ranging from 0.01 nM to 10 μM and viral titers in cell culture supernatants collected at 24 h p.i. were determined. For HCoV-229E-infected Huh-7 cells, we measured an EC<sub>50</sub> value of 40 nM. The EC<sub>50</sub> values for HRV A1-infected HeLa cells and PV-infected Vero cells were 400 nM and 100 nM, respectively (<xref rid="fig2" ref-type="fig">Fig. 2</xref>and <xref rid="tbl1" ref-type="table">Table 1</xref>). To assess the cytotoxicity of silvestrol in these cell lines, CC<sub>50</sub> values were determined in MTT assays. CC<sub>50</sub> values of 30 nM for Huh-7 cells, 160 nM for Vero cells and 5 nM for HeLa cells were obtained (Suppl. <xref rid="appsec1" ref-type="sec">Fig. S2</xref>), suggesting that the metabolic activities of these cell lines are very sensitive towards silvestrol treatment. Our findings are in line with the strong inhibitory effects of silvestrol reported previously for a range of cancer cell lines (<xref rid="bib18" ref-type="bibr">Schatz et al., 2011</xref>). The data result in very low selectivity indices for this compound if permanent rather than primary cells were used for infections with the respective viruses (SI ≤ 1.6, <xref rid="tbl1" ref-type="table">Table 1</xref>). Taken together, the data obtained here and in our previous study (<xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>) led us to conclude that permanent cell lines are not suitable for studying antiviral activities of silvestrol and prompted us to use primary cells in subsequent experiments.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>CC<sub>50</sub>, EC<sub>50</sub> and EC<sub>90</sub> values determined for silvestrol-treated cells that were mock infected (CC<sub>50</sub>) or infected with the indicated viruses (EC<sub>50</sub>/EC<sub>90</sub>). MTT assays were performed at 37°C except for cells used for HCoV-229E and HRV A1 infections, which were performed at 33°C (indicated by asterisks). SI, selectivity index. Experiments were done in biological triplicate.</p></caption><alt-text id="alttext0050">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Cells</th><th>Virus</th><th>CC<sub>50</sub> [μM]</th><th>EC<sub>50</sub>/EC<sub>90</sub> [nM]</th><th>SI</th></tr></thead><tbody><tr><td align="left">MRC-5</td><td align="left">HCoV-229E</td><td align="left">>10*</td><td align="left">3/27</td><td align="left">>3330</td></tr><tr><td align="left">MRC-5</td><td align="left">MERS-CoV</td><td align="left">>10</td><td align="left">1.3/12</td><td align="left">>7690</td></tr><tr><td align="left">MRC-5</td><td align="left">HRV A1</td><td align="left">>10*</td><td align="left">100/900</td><td align="left">>100</td></tr><tr><td align="left">MRC-5</td><td align="left">PV</td><td align="left">>10</td><td align="left">20/180</td><td align="left">>500</td></tr><tr><td align="left">PBMCs</td><td align="left">HCoV-229E</td><td align="left">>1*</td><td align="left">2.8/25</td><td align="left">>350</td></tr><tr><td align="left">Huh-7</td><td align="left">HCoV-229E</td><td align="left">0.03*</td><td align="left">40/360</td><td align="left">0.75</td></tr><tr><td align="left">HeLa</td><td align="left">HRV A1</td><td align="left">0.005*</td><td align="left">400/3600</td><td align="left">0.012</td></tr><tr><td align="left">Vero</td><td align="left">PV</td><td align="left">0.16</td><td align="left">100/900</td><td align="left">1.6</td></tr></tbody></table></table-wrap><fig id="fig2"><label>Fig. 2</label><caption><p>Effects of silvestrol in cancer cell lines and Vero cells infected with HCoV-229E, HRV A1 and PV, respectively. Cells were infected with an MOI of 0.1 and grown in cell culture medium containing different concentrations of silvestrol. 24 h p.i., cell culture supernatants were collected and virus titers were analyzed via plaque assay. Virus titers (in percent) were calculated in relation to infected controls without silvestrol treatment, and EC<sub>50</sub> values were calculated using non-linear regression analysis. Experiments were done in biological triplicate.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"></graphic></fig></p><p id="p0100">In our previous study, specific and potent antiviral activity of silvestrol was observed in EBOV-infected primary human macrophages (<xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>). We therefore decided to assess potential antiviral activities in human primary cells susceptible to the human corona- and picornaviruses used in this study. Human embryonic lung fibroblasts (MRC-5 cells) were infected with HCoV-229E, MERS-CoV, HRV A1 or PV at an MOI of 0.1 and silvestrol was added to the cell culture medium at concentrations ranging from 0.1 nM to 1 μM. Again, viral titers were determined 24 h p.i.. For HCoV-229E and MERS-CoV, EC<sub>50</sub> values of 3 nM and 1.3 nM, respectively, were obtained (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A, B, Suppl. <xref rid="appsec1" ref-type="sec">Fig. S3</xref>A, B and <xref rid="tbl1" ref-type="table">Table 1</xref>). The cytotoxicity of silvestrol was measured using MRC-5 cells that were grown in the presence of varying concentrations of silvestrol for 24 h at 33 °C (corresponding to the temperature used for HCoV-229E and HRV A1 infections) or 37 °C (corresponding to the temperature used for MERS-CoV and PV infections). CC<sub>50</sub> values of > 10 µM were measured at both temperatures (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, see also <xref rid="tbl1" ref-type="table">Table 1</xref>). The resulting selectivity indiceswere > 3330 for HCoV-229E and > 7690 for MERS-CoV, demonstrating low cytotoxicity and extremely efficient antiviral activity of silvestrol in primary cells (<xref rid="tbl1" ref-type="table">Table 1</xref>). The EC<sub>50</sub> values determined for HRV A1- and PV-infected MRC-5 cells were approximately 100 nM and 20 nM (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C, D, Suppl. <xref rid="appsec1" ref-type="sec">Fig. S3</xref>C, D and <xref rid="tbl1" ref-type="table">Table 1</xref>), respectively, suggesting that silvestrol also displays antiviral activities if the respective virus utilizes eIF4A-dependent IRES-driven translation mechanisms. However, HRV A1 was ∼30- to 80-fold and PV ∼7- to 15-fold less sensitive to silvestrol treatment compared with the two coronaviruses included in this study (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A–D), indicating a less prominent role of eIF4A in translation initiation of the picornaviral mRNAs. In summary, the data obtained in this and our previous study (<xref rid="bib1" ref-type="bibr">Biedenkopf et al., 2017</xref>) demonstrate that silvestrol is a potent antiviral inhibitor in primary cells infected with coronaviruses and EBOV. Importantly, the type I IRES-containing PV and, to a lesser extent, HRV A1 also proved to be sensitive to silvestrol treatment in primary cells. Altogether, these findings reveal a broad-spectrum antiviral activity of silvestrol, including viruses with 5′-capped and structured 5′ UTRs as well as those containing IRES elements that require eIF4A helicase activity for efficient translation initiation.<fig id="fig3"><label>Fig. 3</label><caption><p>Antiviral activity of silvestrol against (+) ssRNA viruses that utilize canonical (cap-dependent) translation initiation (coronaviruses) or IRES-driven translation initiation mechanisms (members of the genus <italic>Enterovirus</italic>). Cells were infected with the indicated viruses at an MOI of 0.1 and grown in the presence of different concentrations of silvestrol. Supernatants collected at 24 h p.i. were used to determine viral titers. <bold>A</bold>, HCoV-229E, MRC-5 cells; <bold>B</bold>, MERS-CoV, MRC-5 cells; <bold>C</bold>, HRV A1, MRC-5 cells; <bold>D</bold>, PV, MRC-5 cells; <bold>E</bold>, HCoV-229E, PBMCs. Virus titers (in percent) were calculated in relation to infected controls without silvestrol treatment, and EC<sub>50</sub> values were calculated using non-linear regression analysis. Experiments were done in biological triplicate.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"></graphic></fig><fig id="fig4"><label>Fig. 4</label><caption><p>Analyses of cell cytotoxicity of silvestrol. Effects of silvestrol on cell proliferation were measured by an MTT assay. MRC-5 cells or PBMCs were incubated with the indicated silvestrol concentrations and MTT assays were performed after 24 h. Results were based on three independent experiments (biological triplicates).</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"></graphic></fig></p><p id="p0105">Anticoronaviral effects of silvestrol were further corroborated using peripheral blood mononuclear cells (PBMCs) isolated from human donors and infected with HCoV-229E. For PBMCs, a CC<sub>50</sub> value of > 1 µM was determined (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C), and EC<sub>50</sub> values of 2.8 nM and 3.5 nM, respectively, were obtained using cells from two independent donors (<xref rid="fig3" ref-type="fig">Fig. 3</xref>E, Suppl. <xref rid="appsec1" ref-type="sec">Fig. S3</xref>E, <xref rid="tbl1" ref-type="table">Table 1</xref> and data not shown), confirming the potent antiviral activities of silvestrol in coronavirus-infected primary cells.</p></sec><sec id="sec3.3"><label>3.3</label><title>Silvestrol inhibits the formation of replication/transcription complexes, viral RNA synthesis and the translation of HCoV-229E proteins</title><p id="p0110">In an additional set of experiments, we investigated potential effects of silvestrol on replication/transcription complex (RTC) formation and viral protein accumulation in coronavirus-infected cells. MRC-5 cells were infected with HCoV-229E at an MOI of 3 and treated with the indicated concentrations of silvestrol or left untreated. At 12 h p.i., the cells were harvested for further analyses. Immunofluorescence demonstrated a dose-dependent antiviral effect of silvestrol (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). In the presence of 10 nM silvestrol, we observed a significant decrease of both viral double-stranded RNA (dsRNA) and the HCoV-229E nsp8 protein, which were used as markers for viral genome expression and RTC formation (<xref rid="bib9" ref-type="bibr">Lundin et al., 2014</xref>, <xref rid="bib11" ref-type="bibr">Müller et al., 2016</xref>). At 100 nM silvestrol, nearly no viral dsRNA and nsp8 could be detected (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). The data suggest impaired RTC formation in HCoV-229E-infected MRC-5 cells treated with ≥ 10 nM silvestrol.<fig id="fig5"><label>Fig. 5</label><caption><p>Immunofluorescence analysis to visualize the effects of silvestrol on viral dsRNA and nsp8 accumulation in HCoV-229E-infected MRC-5 cells. Cells were infected with an MOI of 3 and incubated with the indicated silvestrol concentrations. Cells were fixed at 12 h p.i. and analyzed by confocal microscopy using specific antibodies for dsRNA (red) and nonstructural protein 8 (nsp8, green). The scale bar in the overview pictures represents 50 µm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)</p></caption><alt-text id="alttext0040">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"></graphic></fig></p><p id="p0115">In Western blot experiments, N and nsp8 protein accumulation in HCoV-229E-infected Huh-7 cells appeared to be unaffected by silvestrol concentrations of up to 10 nM, whereas both proteins became essentially undetectable at 100 nM silvestrol (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). In contrast to Huh-7 cells, silvestrol severely decreased viral protein synthesis in primary cells already at much lower concentrations, with very low amounts of N and nsp8 proteins being produced in the presence of 10 nM silvestrol in HCoV-229E-infected MRC-5 cells (at 12 h as well as 48 h p.i.; <xref rid="fig6" ref-type="fig">Fig. 6</xref>B). The data correspond very well to the virus titration EC<sub>50</sub> data shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>, <xref rid="fig3" ref-type="fig">Fig. 3</xref> for permanent cell lines versus primary cells and support our conclusion that specific antiviral effects of silvestrol against HCoV-229E are largely confined to primary cells.<fig id="fig6"><label>Fig. 6</label><caption><p>Western blot analysis of HCoV-229E protein accumulation in the presence of silvestrol. (<bold>A</bold>) Huh-7 and (<bold>B</bold>) MRC-5 cells, respectively, were infected with HCoV-229E at an MOI of 3 and treated with the indicated concentrations of silvestrol. Cell lysates were prepared at 12 h p.i. and 48 h p.i. as indicated and the accumulation of viral N and nsp8 proteins was determined by Western blot analysis using appropriate antibodies (see Materials and Methods). β-actin was used as a loading control. Experiments were done in biological duplicates. Panels A and B show representative experiments.</p></caption><alt-text id="alttext0045">Fig. 6</alt-text><graphic xlink:href="gr6_lrg"></graphic></fig></p><p id="p0120">Taken together, the data lead us to conclude that the natural compound silvestrol is a potent antiviral molecule with broad-spectrum activity, now demonstrated for mechanistically diverse (−) and (+) ssRNA viruses. Importantly, silvestrol had no major cytotoxic side effects in the primary cell systems analyzed in this study. This is in line with several studies that explored the effect of silvestrol in different cancer model systems. For example, no general toxicity of silvestrol could be detected <italic>in vivo</italic> in the liver, spleen or on blood cells; likewise, no general disease symptoms, loss of body weight or immune suppressive effects were observed (<xref rid="bib8" ref-type="bibr">Lucas et al., 2009</xref>, <xref rid="bib3" ref-type="bibr">Cencic et al., 2009</xref>, <xref rid="bib13" ref-type="bibr">Patton et al., 2015</xref>). Moreover, silvestrol showed favorable pharmacokinetics in terms of bioavailability and biostability (<xref rid="bib17" ref-type="bibr">Saradhi et al., 2011</xref>). In our opinion, silvestrol-mediated eIF4A inhibition is a promising new strategy for combating pathogenic RNA viruses. For therapeutic intervention, the short-term application of low doses of silvestrol to reduce viral titers in the patient should be an acceptable safety risk. Specific inhibition of cellular factors, such as eIF4A, that promote the translation of structured viral transcripts should limit viral replication to low levels and thus help the immune system in establishing effective antiviral responses. Clearly, the observed antiviral effects of silvestrol need to be characterized in suitable <italic>in vivo</italic> infection models to validate its promising therapeutic potential.</p></sec></sec><sec id="sec4"><title>Disclosure statement</title><p id="p0125">The authors declare no conflict of interest.</p></sec><sec id="sec5"><title>Funding</title><p id="p0130">The work was supported by the <funding-source id="gs1">German Center for Infection Research</funding-source> (DZIF), partner site Giessen, Germany (TTU Emerging Infections, to S.P. and J.Z.), <funding-source id="gs2">German Research Foundation</funding-source> (DFG) grant CRC 1021 (to J.Z. and R.K.H., respectively), LOEWE Research Center DRUID (to A.G. and J.Z.) and the <funding-source id="gs3">LOEWE Research Cluster “Medical RNomics”</funding-source> grant 519/03/00.001-(0003) (to A.G. and R.K.H.).</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Biedenkopf</surname><given-names>N.</given-names></name><name><surname>Lange-Grünweller</surname><given-names>K.</given-names></name><name><surname>Schulte</surname><given-names>F.W.</given-names></name></person-group><article-title>The natural compound silvestrol is a potent inhibitor of Ebola virus replication</article-title><source>Antivir. Res.</source><volume>137</volume><year>2017</year><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">27864075</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Bordeleau</surname><given-names>M.E.</given-names></name><name><surname>Mori</surname><given-names>A.</given-names></name><name><surname>Oberer</surname><given-names>M.</given-names></name></person-group><article-title>Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A</article-title><source>Nat. Chem. Biol.</source><volume>2</volume><year>2006</year><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">16532013</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Cencic</surname><given-names>R.</given-names></name><name><surname>Carrier</surname><given-names>M.</given-names></name><name><surname>Galicia-Vázquez</surname><given-names>G.</given-names></name></person-group><article-title>Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol</article-title><source>PLos One</source><volume>4</volume><year>2009</year><object-id pub-id-type="publisher-id">e5223</object-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>J.</given-names></name><name><surname>Galicia-Vázquez</surname><given-names>G.</given-names></name><name><surname>Cencic</surname><given-names>R.</given-names></name></person-group><article-title>CRISPR-mediated drug-target validation reveals selective pharmacological inhibition of the RNA helicase, eIF4A</article-title><source>Cell Rep</source><volume>15</volume><year>2016</year><fpage>2340</fpage><lpage>2347</lpage><pub-id pub-id-type="pmid">27239032</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hinnebusch</surname><given-names>A.G.</given-names></name><name><surname>Ivanov</surname><given-names>I.P.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Translational control by 5'-untranslated regions of eukaryotic mRNAs</article-title><source>Science</source><volume>352</volume><year>2016</year><fpage>1413</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">27313038</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Kogure</surname><given-names>T.</given-names></name><name><surname>Kinghorn</surname><given-names>A.D.</given-names></name><name><surname>Yan</surname><given-names>I.</given-names></name></person-group><article-title>Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer</article-title><source>PLos One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e76136</object-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.M.</given-names></name><name><surname>Chen</surname><given-names>C.J.</given-names></name><name><surname>Shih</surname><given-names>S.R.</given-names></name></person-group><article-title>Regulation mechanisms of viral IRES-driven translation</article-title><source>Trends Microbiol.</source><volume>25</volume><year>2017</year><fpage>546</fpage><lpage>561</lpage><comment>(Review)</comment><pub-id pub-id-type="pmid">28242053</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>D.M.</given-names></name><name><surname>Edwards</surname><given-names>R.B.</given-names></name><name><surname>Lozanski</surname><given-names>G.</given-names></name></person-group><article-title>The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo</article-title><source>Blood</source><volume>113</volume><year>2009</year><fpage>4656</fpage><lpage>4666</lpage><pub-id pub-id-type="pmid">19190247</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Lundin</surname><given-names>A.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name><name><surname>Bergström</surname><given-names>T.</given-names></name><name><surname>Kann</surname><given-names>N.</given-names></name><name><surname>Adamiak</surname><given-names>B.</given-names></name><name><surname>Hannoun</surname><given-names>C.</given-names></name><name><surname>Kindler</surname><given-names>E.</given-names></name><name><surname>Jónsdóttir</surname><given-names>H.R.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Kint</surname><given-names>J.</given-names></name><name><surname>Forlenza</surname><given-names>M.</given-names></name><name><surname>Müller</surname><given-names>M.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Trybala</surname><given-names>E.</given-names></name></person-group><article-title>Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus</article-title><source>PLoS Pathog.</source><volume>10</volume><year>2014</year><object-id pub-id-type="publisher-id">e1004166</object-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Madhugiri</surname><given-names>R.</given-names></name><name><surname>Fricke</surname><given-names>M.</given-names></name><name><surname>Marz</surname><given-names>M.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name></person-group><article-title>Coronavirus cis-acting RNA elements</article-title><source>Adv. Virus Res.</source><volume>96</volume><year>2016</year><fpage>127</fpage><lpage>163</lpage><comment>Review</comment><pub-id pub-id-type="pmid">27712622</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>C.</given-names></name><name><surname>Karl</surname><given-names>N.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name></person-group><article-title>D, L-lysine acetylsalicylate and glycine impairs Coronavirus Replication</article-title><source>J Antivir Antiretrovir</source><volume>8</volume><year>2016</year><fpage>142</fpage><lpage>150</lpage></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Woodard</surname><given-names>J.L.</given-names></name><name><surname>Lucas</surname><given-names>D.M.</given-names></name></person-group><article-title>Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species</article-title><source>Nat. Prod. Rep.</source><volume>31</volume><year>2014</year><fpage>924</fpage><lpage>939</lpage><comment>Review</comment><pub-id pub-id-type="pmid">24788392</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Patton</surname><given-names>J.T.</given-names></name><name><surname>Lustberg</surname><given-names>M.E.</given-names></name><name><surname>Lozanski</surname><given-names>G.</given-names></name></person-group><article-title>The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>2693</fpage><lpage>2708</lpage><pub-id pub-id-type="pmid">25393910</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Graff</surname><given-names>J.</given-names></name><name><surname>Ruggero</surname><given-names>D.</given-names></name><name><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group><article-title>Targeting the eIF4F translation initiation complex: a critical nexus for cancer development</article-title><source>Cancer Res.</source><volume>75</volume><year>2015</year><fpage>250</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">25593033</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Rubio</surname><given-names>C.A.</given-names></name><name><surname>Weisburd</surname><given-names>B.</given-names></name><name><surname>Holderfield</surname><given-names>M.</given-names></name></person-group><article-title>Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation</article-title><source>Genome Biol.</source><volume>15</volume><issue>10</issue><year>2014</year><fpage>476</fpage><pub-id pub-id-type="pmid">25273840</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Sadlish</surname><given-names>H.</given-names></name><name><surname>Galicia-Vazquez</surname><given-names>G.</given-names></name><name><surname>Paris</surname><given-names>C.G.</given-names></name></person-group><article-title>Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex</article-title><source>ACS Chem. Biol.</source><volume>8</volume><year>2013</year><fpage>1519</fpage><lpage>1527</lpage><pub-id pub-id-type="pmid">23614532</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Saradhi</surname><given-names>U.V.</given-names></name><name><surname>Gupta</surname><given-names>S.V.</given-names></name><name><surname>Chiu</surname><given-names>M.</given-names></name></person-group><article-title>Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry</article-title><source>AAPS J.</source><volume>13</volume><year>2011</year><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">21499689</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Schatz</surname><given-names>J.H.</given-names></name><name><surname>Oricchio</surname><given-names>E.</given-names></name><name><surname>Wolfe</surname><given-names>A.L.</given-names></name></person-group><article-title>Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma</article-title><source>J. Exp. Med.</source><volume>208</volume><year>2011</year><fpage>1799</fpage><lpage>1807</lpage><pub-id pub-id-type="pmid">21859846</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Schlereth</surname><given-names>J.</given-names></name><name><surname>Grünweller</surname><given-names>A.</given-names></name><name><surname>Biedenkopf</surname><given-names>N.</given-names></name></person-group><article-title>RNA binding specificity of Ebola virus transcription factor VP30</article-title><source>RNA Biol.</source><volume>17</volume><year>2016</year><fpage>1</fpage><lpage>16</lpage><comment>([Epub ahead of print])</comment></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Su</surname><given-names>B.N.</given-names></name><name><surname>Chai</surname><given-names>H.</given-names></name><name><surname>Mi</surname><given-names>Q.</given-names></name></person-group><article-title>Activity-guided isolation of cytotoxic constituents from the bark of Aglaia crassinervia collected in Indonesia</article-title><source>Bioorg. Med. Chem.</source><volume>14</volume><year>2006</year><fpage>960</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">16216518</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>S.R.</given-names></name></person-group><source>Trends Microbiol.</source><volume>20</volume><year>2012</year><fpage>558</fpage><lpage>566</lpage><comment>(Review)</comment><pub-id pub-id-type="pmid">22944245</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Weik</surname><given-names>M.</given-names></name><name><surname>Modrof</surname><given-names>J.</given-names></name><name><surname>Klenk</surname><given-names>H.D.</given-names></name></person-group><article-title>Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation</article-title><source>J. Virol.</source><volume>76</volume><year>2002</year><fpage>8532</fpage><lpage>8539</lpage><pub-id pub-id-type="pmid">12163572</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.Y.</given-names></name><name><surname>Lavrik</surname><given-names>I.N.</given-names></name><name><surname>Mahlknecht</surname><given-names>U.</given-names></name></person-group><article-title>The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities</article-title><source>Int. J. Canc.</source><volume>121</volume><year>2007</year><fpage>839</fpage><lpage>846</lpage></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Siddell</surname><given-names>S.G.</given-names></name></person-group><article-title>Processing of the human coronavirus 229E replicase polyproteins by the virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to pp1a and pp1ab</article-title><source>J. Virol.</source><volume>73</volume><year>1999</year><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">9847320</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0140">The following is the supplementary data related to this article:</p><p id="p0145">Fig. S1: Effects of 5 and 10 nM silvestrol on reporter gene expression in the context of the 5′UTR from CSFV. Values were normalized to corresponding DMSO controls. Standard errors of the mean of 16 independent experiments are shown.</p><p id="p0150">Fig. S2: Analyses of cell cytotoxicity of silvestrol. Effects of silvestrol on cell proliferation were measured by a MTT-assay. Huh-7 cells, Vero cells or HeLa cells were incubated with the indicated silvestrol concentrations and MTT-assays were performed after 24 h. Results were based on three independent experiments (biological triplicates).</p><p id="p0155">Fig. S3: Effects of silvestrol in cancer cell lines and Vero cells infected with HCoV-229E, HRV A1 and PV, respectively. Cells were infected with an MOI of 0.1 and grown in cell culture medium containing different concentrations of silvestrol. 24 h p.i., cell culture supernatants were collected and virus titers were analyzed via plaque assays (plaque forming units (pfu) per ml). Results were based on three independent experiments (biological triplicates).</p><p id="p0160">Fig. S4: Antiviral activity of silvestrol in <bold>A</bold>, HCoV-229E-infected MRC-5 cells; <bold>B</bold>, MERS-CoV-infected MRC-5 cells; <bold>C</bold>, HRV A1-infected MRC-5 cells; <bold>D</bold>, PV-infected MRC-5 cells; <bold>E</bold>, HCoV-229E-infected PBMC. Cells were infected with the indicated viruses at an MOI of 0.1 and grown in the presence of different concentrations of silvestrol. Supernatants collected at 24 h p.i. were used to determine viral titers via plaque assays (plaque forming units (pfu) per ml). Results were based on three independent experiments (biological triplicates).<supplementary-material content-type="local-data" id="mmc1"><caption><title>mmc1</title></caption><media xlink:href="mmc1.pdf"><alt-text>mmc1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We would like to thank Nadja Karl for excellent technical assistance.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0165">Supplementary data related to this article can be found at <ext-link ext-link-type="doi" xlink:href="10.1016/j.antiviral.2017.12.010" id="intref0010">https://doi.org/10.1016/j.antiviral.2017.12.010</ext-link>.</p></fn></fn-group></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7113723
|texte= Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:29258862" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |